Atherosclerotic cardiovascular disease

This study looks at whether alirocumab, a drug that lowers cholesterol, can reduce the risk of heart attack, stroke, or death in people who have hardened arteries but have never had a heart attack or stroke before. Researchers will analyze data from routine medical care to compar…

This study tests whether a nurse-led smoking cessation program with free drugs and follow-up at healthy life centers helps heart patients quit smoking better than just giving them written information. About 221 daily smokers hospitalized for a heart event will be split into two g…

This study tested a drug called pelacarsen in 422 Black/African American and Hispanic patients with high Lp(a) levels and existing heart disease. Lp(a) is a genetic risk factor for heart attacks and strokes. The goal was to see if pelacarsen could safely lower Lp(a) levels over 1…

This study tested whether a twice-yearly injection (inclisiran) lowers LDL cholesterol better than a daily pill (bempedoic acid) in 402 adults with heart disease who still have high cholesterol despite taking statins. Participants received either inclisiran or bempedoic acid on t…

This Phase 3 trial is testing whether a monthly injection of ziltivekimab can reduce the risk of heart attacks and strokes in 6,200 people who already have heart disease, chronic kidney disease, and signs of inflammation. Participants receive either the drug or a placebo for up t…

This large study looks at real-world data from 60,000 people with type 2 diabetes and obesity to compare four diabetes drugs—dulaglutide, semaglutide, tirzepatide, and sitagliptin—in preventing heart attacks, strokes, and death. Researchers are analyzing insurance claims to see w…

This study tests whether having a pharmacist call both patients with heart disease and their doctors can increase the use of high-intensity statins—powerful cholesterol-lowering drugs that prevent future heart problems. The trial includes adults aged 18 to 75 with atherosclerotic…

This completed study looked at two diabetes drugs, tirzepatide and sitagliptin, to see which one better prevents heart attacks, strokes, or death in people with type 2 diabetes and heart disease. Researchers analyzed data from over 49,000 patients. The goal was to learn how well …

This study tested a drug called olezarsen in 154 adults with high triglycerides (a type of blood fat) and either heart disease or very high triglycerides. Participants received injections of the drug or a placebo for up to 12 months. The main goal was to see if the drug could low…

This study tested a digital quality improvement program to help doctors better manage LDL (bad) cholesterol in patients with heart disease. Over 1,400 adults with established cardiovascular disease participated. The program used smartphone tools to improve treatment and follow gu…

This phase 2 trial tested olpasiran, an injectable drug, in 281 adults with high lipoprotein(a) – a genetic risk factor for heart disease. Participants received either olpasiran or a placebo. The main goal was to see how much the drug lowered Lp(a) levels after 36 weeks. Results …

This study tested a new drug called AZD0780 in 202 people with heart disease or related risks and high LDL cholesterol. Participants took either the drug or a placebo for 4 weeks, and researchers measured changes in blood pressure using a 24-hour monitor. The goal was to see if A…

This Phase 3 study tested a drug called olezarsen in 1,478 people with very high triglycerides (a type of blood fat) and either heart disease or a high risk for it. Participants received either olezarsen or a placebo as a shot under the skin. The main goal was to see if olezarsen…

This study looked at whether a once-weekly medicine called semaglutide (used for weight loss and diabetes) can lower the risk of heart attacks, strokes, and death in people with overweight or obesity. Researchers analyzed medical records of over 285,000 people in the US. The goal…

This early-stage trial tested a new drug called AZD4144 in 29 people who have both heart disease and chronic kidney disease. The main goal was to see if the drug is safe and if it lowers certain markers of inflammation in the blood. The study compared the drug against a placebo o…

This study looked at 3048 adults with heart or blood vessel disease to see if lowering LDL ('bad') cholesterol to a very low level (below 55 mg/dL) is better than the standard target (below 70 mg/dL). Participants received either a statin alone or a statin plus ezetimibe. The goa…

This study tested whether a nurse-led program could help veterans with HIV lower their blood pressure and reduce their risk of heart disease. 305 veterans with HIV and high blood pressure took part. The program used video visits and care coordination to help manage blood pressure…

This Phase 3 trial tested a daily pill combining two drugs, obicetrapib and ezetimibe, in 407 people with inherited high cholesterol or heart disease. Participants took the combination or a placebo on top of their usual cholesterol meds. The main goal was to see if the combo lowe…

This completed study looked at medical records from over 10,000 men with enlarged prostate (BPH) in the UK and China. Researchers wanted to see if men taking 5-alpha reductase inhibitors (drugs like finasteride) had fewer heart problems like heart attacks and strokes. The study c…

This study tested a new drug called obicetrapib in over 2,500 people with high cholesterol that wasn't well controlled by their current treatments. Participants took either a 10 mg obicetrapib pill or a placebo daily for about 6 months. The main goal was to see if obicetrapib cou…

This study tested whether adding ezetimibe to atorvastatin (a common cholesterol drug) works better than atorvastatin alone in people at very high risk for heart attacks or strokes. Researchers enrolled 137 adults with atherosclerotic cardiovascular disease and measured how much …

Researchers are testing whether nicotinamide riboside, a form of vitamin B3 sold as a supplement, can reduce immune system activation in people with mild to moderate psoriasis. The trial enrolls adults aged 18 to 80 who are not on biologic therapy. Participants take either the su…

This completed study looked at insurance claims data from 70,000 people with type 2 diabetes and established heart disease to compare the heart-related risks of three diabetes drugs: tirzepatide, dulaglutide, and semaglutide. The goal was to see if any of these drugs was linked t…

This completed study observed over 4,500 adults with atherosclerotic cardiovascular disease who had never had a heart attack or stroke. Researchers compared those taking alirocumab (a cholesterol-lowering drug) to those not on similar therapy, using real-world data to see if the …

This study looks at two medicines, alirocumab and inclisiran, that help lower bad cholesterol (LDL-C) in people with heart disease. Researchers will use real-world data from about 124 patients to see which drug reduces cholesterol more over time. The goal is to understand how the…

This study looked at 233 people with heart or blood vessel disease who had calcium buildup in their heart arteries found by chance on a chest CT scan. Researchers wanted to see if telling both the patient and their doctor about this finding would encourage them to start cholester…

This study surveyed 608 heart and kidney doctors to understand their awareness and use of a blood test called hsCRP, which measures inflammation. The goal was to learn what doctors think about inflammation's role in treating patients with heart disease, kidney disease, or heart f…

This completed study examined blood samples from 40 adults to see if high levels of lipoprotein (a), a type of cholesterol, are linked to fewer or different blood vessel repair cells. Participants with high Lp(a) were compared to those with normal levels. The goal was to better u…

This study surveyed 1,500 Chinese heart and kidney specialists to understand their awareness and perceptions of systemic inflammation in patients with both atherosclerotic cardiovascular disease and chronic kidney disease. The goal was to learn how doctors currently identify and …

This completed study in Egypt examined 1,000 adults with heart disease to see how many reached their LDL cholesterol targets and what got in the way. Participants provided a fasting lipid profile, and researchers looked for patterns and barriers. The goal is to find better ways t…

This study looked at nearly 40,000 people with a history of heart disease caused by clogged arteries. The goal was to measure their levels of lipoprotein(a), a fatty substance that can increase heart risk. Researchers wanted to see how these levels vary by age, sex, race, and reg…

This study used national health survey data to estimate how many US adults with high cholesterol might be eligible for a new drug called inclisiran. Researchers also calculated how many heart attacks and strokes could be prevented over 10 years if these patients took the drug. Th…